Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753124 | 0.80 | CYP3A4 (0.80) | CYP17A1CYP3A4CYP2C9CYP2C19RORC | |
| SCHEMBL14833287 | 0.74 | RORC (0.37) | CYP17A1CYP3A4CYP2C9CYP2C19RORC | |
| SCHEMBL9598133 | 0.72 | ALOX5 (0.74) | ALOX5 | |
| SCHEMBL5751050 | 0.70 | CYP17A1 (0.44) | CYP17A1CYP3A4CYP11B2CYP11B1CYP1A2 | |
| SCHEMBL14757482 | 0.69 | CYP3A4 (1.00) | CYP17A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13262555 | 0.67 | CYP1A2 (0.48) | CYP1A2 | |
| SCHEMBL9420901 | 0.66 | CYP1A2 (0.52) | CYP17A1CYP11B2CYP11B1CYP1A2 | |
| SCHEMBL14762264 | 0.66 | ALDH1A1 (0.48) | CYP17A1CYP1A2 | |
| SCHEMBL6935441 | 0.66 | LMNA (0.49) | — | |
| SCHEMBL9838482 | 0.66 | CYP1A2 (0.47) | CYP17A1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084149-B2 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| EP-1073640-B1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030236274-A1 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6573289-B1 | Naphthalene derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1073640-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054309-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236274-A1 | Naphthalene derivatives, their production and use | CYP17A1, CYP21A2, HSD17B1 | CYP17A1 1/4885CYP3A4 214/4885CYP2C9 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.